Overview

Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
To study induction therapy with Nab-paclitaxel, Cisplatin and Pembrolizumab in patients with Locally Advanced HNSCC.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong Provincial People's Hospital
Treatments:
Paclitaxel
Pembrolizumab